# Mitsubishi Gas Chemical

> Mitsubishi Gas Chemical is a VC fund backing Chemical and Pharmaceutical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 8
- Last investment: Mar 2025
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mgc-pure-chemicals-singapore-pte-ltd/
- X (Twitter): https://twitter.com/mgc_ageless
- Website: http://www.mgc.co.jp/eng/index.html

Mitsubishi Gas Chemical is a VC fund in Tokyo focused on Chemical and Pharmaceutical. MGC Group does business in a wide range of fields, from basic chemicals to fine chemicals and functional materials.MGC philosophy for being is “to contribute to societal growth and harmony by creating a wide range of value through chemistry.” Thus They seek to be “a leading chemicals group with a major presence and a strong platform ofproprietary technology.” As such, They work constantly to create new technologies and values and to grow hand in hand with society.

## Contacts

5 contacts available for Mitsubishi Gas Chemical. Shizune tracks 1 team members at Mitsubishi Gas Chemical. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mitsubishi-gas-chemical?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $50M–$60M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Chemical | 2 | 25% |
| Pharmaceutical | 2 | 25% |
| Medical | 1 | 13% |
| CleanTech | 1 | 13% |
| GreenTech | 1 | 13% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Funding Round | 2 | 25% |
| Seed | 1 | 13% |
| Series B | 1 | 13% |
| Corporate Round | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 3 | 38% |
| United States | 2 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kenichiro Usuda | Researcher, Advanced Business Development Division | 0 | https://shizune.co/investors/profile/kenichiro-usuda |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Resource Chemical | Resource Chemical develops CO2 into high-performance plastics that do not pollute the environment. The company's headquarters are in Berkeley, California. | $15M |  | Mar 06, 2025 |  |
| TKG Therapeutics | Tokyo Nucleic Acid Synthesis is a pharmaceutical company that focuses on developing nucleic acid drugs using new-age medical technology. | $1M | Seed | Jan 31, 2024 |  |
| Albatross Technology | Albatross Technology is a technology company that develops offshore renewable energy devices and floating offshore wind turbines. | $2.9M | Series A | Dec 06, 2023 |  |
| Elephantech | Elephantech makes electric industry more sustainable with metal inkjet printing technology. | $311.8M |  | Oct 17, 2022 |  |
| Elephantech | Elephantech makes electric industry more sustainable with metal inkjet printing technology. | $14.4M | Corporate Round | Oct 17, 2022 |  |
| Origin Materials | Origin is the carbon negative materials company. The Origin platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Origin has developed a platform for turning the carbon found in inexpensive, plentiful, non-food biomass such as sustainable wood residuesinto useful materials while capturing carbon in the process. Origin’s patented technology platform can help revolutionize the production of a wide range of end products, including clothing, textiles, plastics, packaging, car parts, tires, carpeting, toys, and more with a ~$1 trillion addressable market. | $200M | Post-IPO Equity | Jun 25, 2021 |  |
| Veritas In Silico | Veritas In Silico is a start-up to research and sales of pharmaceuticals.Veritas In Silico, target partial structures in messenger RNA (mRNA) by exploring the true form of RNA, the origin of life, based on in silico (computer-based computational science) technology Established a drug discovery system with a completely new concept.This mRNA-targeteddrug has the potential to be applied to any disease, including those for which it has been difficult to develop therapeutic drugs using conventional protein-based drug discovery. Therefore, it is expected to be a favorite for next-generation drug discovery that will cause a paradigm shift in the pharmaceutical industry. | $113.4M | Series B | Mar 29, 2019 |  |
| Veritas In Silico | Veritas In Silico is a start-up to research and sales of pharmaceuticals.Veritas In Silico, target partial structures in messenger RNA (mRNA) by exploring the true form of RNA, the origin of life, based on in silico (computer-based computational science) technology Established a drug discovery system with a completely new concept.This mRNA-targeteddrug has the potential to be applied to any disease, including those for which it has been difficult to develop therapeutic drugs using conventional protein-based drug discovery. Therefore, it is expected to be a favorite for next-generation drug discovery that will cause a paradigm shift in the pharmaceutical industry. | $49.6M | Series A | May 31, 2017 |  |

8 of 8 investments shown.

## Co-investors
- [ANRI](https://shizune.co/investors/profile/anri) — VC Fund, 2 deals together
- [Beyond Next Ventures](https://shizune.co/investors/profile/beyond-next-ventures) — VC Fund, 2 deals together
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund, 2 deals together
- [EIWA](https://shizune.co/investors/profile/eiwa-8d95) — VC Fund, 2 deals together
- [Kanbishi](https://shizune.co/investors/profile/kanbishi) — VC Fund, 2 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Life Science Investors in Japan](https://shizune.co/investors/life-science-investors-japan)
- [Life Science VC Funds in Japan](https://shizune.co/investors/life-science-vc-funds-japan)

## FAQ

### What does Mitsubishi Gas Chemical invest in?

Mitsubishi Gas Chemical invests primarily in Chemical, Pharmaceutical and Medical startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Mitsubishi Gas Chemical's check size?

Mitsubishi Gas Chemical typically joins rounds of $50M–$60M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mitsubishi Gas Chemical participates in.

### How do I contact Mitsubishi Gas Chemical?

Public channels for Mitsubishi Gas Chemical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mitsubishi Gas Chemical?

The team at Mitsubishi Gas Chemical includes Kenichiro Usuda (Researcher, Advanced Business Development Division). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co